122 related articles for article (PubMed ID: 8494733)
1. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Br J Cancer; 1993 May; 67(5):996-1000. PubMed ID: 8494733
[TBL] [Abstract][Full Text] [Related]
2. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Cancer Chemother Pharmacol; 1994; 33(6):497-503. PubMed ID: 8137461
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract][Full Text] [Related]
4. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Mellish KJ; Kelland LR; Harrap KR
Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
[TBL] [Abstract][Full Text] [Related]
5. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
6. Antitumor-activity of orally-administered ammine amine platinum (iv) dicarboxylate complexes against a panel of human ovarian-carcinoma xenografts.
Kelland L; Jones M; Gwynne J; Valenti M; Murrer B; Barnard C; Vollano J; Giandomenico C; Abrams M; Harrap K
Int J Oncol; 1993 Jun; 2(6):1043-8. PubMed ID: 21573668
[TBL] [Abstract][Full Text] [Related]
7. Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats.
Wolfgang GH; Dominick MA; Walsh KM; Hoeschele JD; Pegg DG
Fundam Appl Toxicol; 1994 Jan; 22(1):73-9. PubMed ID: 8125216
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
9. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.
Bregman CL; Williams PD
Cancer Chemother Pharmacol; 1986; 18(2):117-23. PubMed ID: 3539384
[TBL] [Abstract][Full Text] [Related]
10. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.
Orr RM; O'Neill CF; Nicolson MC; Barnard CF; Murrer BA; Giandomenico CM; Vollano JF; Harrap KR
Br J Cancer; 1994 Sep; 70(3):415-20. PubMed ID: 8080724
[TBL] [Abstract][Full Text] [Related]
12. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
13. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
15. Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin.
Yoshida M; Khokhar AR; Kido Y; Ali-Osman F; Siddik ZH
Biochem Pharmacol; 1994 Aug; 48(4):793-9. PubMed ID: 8080453
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of cisplatin and carboplatin on pharmacokinetics, nephrotoxicity and effect on renal nuclear DNA synthesis in rats.
Yasumasu T; Ueda T; Uozumi J; Mihara Y; Kumazawa J
Pharmacol Toxicol; 1992 Feb; 70(2):143-7. PubMed ID: 1508841
[TBL] [Abstract][Full Text] [Related]
17. The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
Ormerod MG; Orr RM; O'Neill CF; Chwalinski T; Titley JC; Kelland LR; Harrap KR
Br J Cancer; 1996 Dec; 74(12):1935-43. PubMed ID: 8980393
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity.
Badary OA; Nagi MN; al-Shabanah OA; al-Sawaf HA; al-Sohaibani MO; al-Bekairi AM
Can J Physiol Pharmacol; 1997 Dec; 75(12):1356-61. PubMed ID: 9534946
[TBL] [Abstract][Full Text] [Related]
19. Effect of oxoplatinum and CBDCA on renal functions in rats.
Láznícková A; Semecký V; Láznícek M; Zubr V; Koksál J; Kvĕtina J
Neoplasma; 1989; 36(2):161-9. PubMed ID: 2654665
[TBL] [Abstract][Full Text] [Related]
20. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
